NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of GNC Holdings Inc. (NYSE:GNC) resulting from allegations that GNC may have issued materially misleading business information to the investing public.
On October 22, 2015, the State of Oregon sued GNC, claiming that GNC’s nutritional and dietary supplements are laced with unapproved drugs, including picamilon, a Russian prescription medicine for neurological conditions, and BMPEA, which was first synthesized in the 1930s as a replacement for amphetamines and never studied in humans. On this news, shares of GNC fell $5.73 per share or over 14% to close at $34.50 per share on October 22, 2015, damaging investors.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by GNC investors. If you purchased shares of GNC on or before October 22, 2015, please visit the firm’s website at http://rosenlegal.com/cases-543.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.